A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
aleglitazar
pioglitazone
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria:
- Adult patients >/= 18 years of age
- Diabetes mellitus, Type 2
- Moderately impaired kidney function
- Drug naive or up to 2 antihyperglycemic medications at stable dose for over 1 month at screening
- BMI 25-35
Exclusion Criteria:
- Current or previous treatment with a thiazolidinedione
- Current or previous treatment with insulin
- Treatment with fibrates <3 months prior to screening
- History of renal disease other than diabetic nephropathy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
aleglitazar
pioglitazone
Arm Description
Outcomes
Primary Outcome Measures
Renal function: estimated glomerular filtration rate
Secondary Outcome Measures
Safety, Tolerability: Adverse events (AEs), laboratory parameters
Renal function: estimated glomerular filtration rate
Effect on blood hemoglobin
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01043029
Brief Title
A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
Official Title
Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
May 2010 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
July 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This multi-center, randomized, double-blind, active controlled, parallel-group study in type 2 diabetes patients with moderate renal impairment will evaluate the effect on renal function and the safety and tolerability of aleglitazar compared with pioglitazone. Patients will be randomized to receive either 150 mcg aleglitazar or 45 mg pioglitazone as daily oral doses. In addition, a diet and exercise plan will also be implemented during the anticipated time on study treatment of 52 weeks. The target sample size is 200-400 patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
302 (Actual)
8. Arms, Groups, and Interventions
Arm Title
aleglitazar
Arm Type
Experimental
Arm Title
pioglitazone
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
aleglitazar
Intervention Description
Aleglitazar 150 mcg po daily for 52 weeks
Intervention Type
Drug
Intervention Name(s)
pioglitazone
Intervention Description
Pioglitazone 45 mg po daily for 52 weeks
Primary Outcome Measure Information:
Title
Renal function: estimated glomerular filtration rate
Time Frame
Week 60
Secondary Outcome Measure Information:
Title
Safety, Tolerability: Adverse events (AEs), laboratory parameters
Time Frame
AEs: Throughout study, laboratory assessments: Week 2, 4, 8, 12, 16, 20, 26, 39, 52, 56, 60
Title
Renal function: estimated glomerular filtration rate
Time Frame
Week 52
Title
Effect on blood hemoglobin
Time Frame
Week 52
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients >/= 18 years of age
Diabetes mellitus, Type 2
Moderately impaired kidney function
Drug naive or up to 2 antihyperglycemic medications at stable dose for over 1 month at screening
BMI 25-35
Exclusion Criteria:
Current or previous treatment with a thiazolidinedione
Current or previous treatment with insulin
Treatment with fibrates <3 months prior to screening
History of renal disease other than diabetic nephropathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
City
St. Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4075
Country
Australia
City
Elizabeth Vale
State/Province
South Australia
ZIP/Postal Code
5112
Country
Australia
City
Richmond
State/Province
South Australia
ZIP/Postal Code
3121
Country
Australia
City
Launceston
State/Province
Tasmania
ZIP/Postal Code
7001
Country
Australia
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
City
Fortaleza
State/Province
CE
ZIP/Postal Code
60135-170
Country
Brazil
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90035-170
Country
Brazil
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01221-020
Country
Brazil
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
04022-001
Country
Brazil
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
04231-030
Country
Brazil
City
Barranquilla
Country
Colombia
City
Bogota
Country
Colombia
City
Bucaramanga
Country
Colombia
City
Medellin-Antioquia
Country
Colombia
City
San Salvador
Country
El Salvador
City
Aschaffenburg
ZIP/Postal Code
63739
Country
Germany
City
Berlin
ZIP/Postal Code
10115
Country
Germany
City
Damme
ZIP/Postal Code
49401
Country
Germany
City
Dresden
ZIP/Postal Code
01307
Country
Germany
City
Essen
ZIP/Postal Code
45359
Country
Germany
City
Falkensee
ZIP/Postal Code
14612
Country
Germany
City
Mainz
ZIP/Postal Code
55116
Country
Germany
City
Münster
ZIP/Postal Code
48145
Country
Germany
City
Neuwied
ZIP/Postal Code
56564
Country
Germany
City
Reichenbach
ZIP/Postal Code
08468
Country
Germany
City
Rostock
ZIP/Postal Code
18059
Country
Germany
City
Sulzbach-Rosenberg
ZIP/Postal Code
92237
Country
Germany
City
Würzburg
ZIP/Postal Code
97072
Country
Germany
City
Hong Kong
Country
Hong Kong
City
Tuen Mun
ZIP/Postal Code
852
Country
Hong Kong
City
Baja
ZIP/Postal Code
6500
Country
Hungary
City
Budapest
ZIP/Postal Code
1036
Country
Hungary
City
Budapest
ZIP/Postal Code
1045
Country
Hungary
City
Budapest
ZIP/Postal Code
1135
Country
Hungary
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
City
Kecskemet
ZIP/Postal Code
6001
Country
Hungary
City
Miskolc
ZIP/Postal Code
3526
Country
Hungary
City
Satoraljaujhely
ZIP/Postal Code
3980
Country
Hungary
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
City
Szekszard
ZIP/Postal Code
7100
Country
Hungary
City
Genova
State/Province
Liguria
ZIP/Postal Code
16132
Country
Italy
City
Bergamo
State/Province
Lombardia
ZIP/Postal Code
20128
Country
Italy
City
Cusano Milanino
State/Province
Lombardia
ZIP/Postal Code
20095
Country
Italy
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20132
Country
Italy
City
Pavia
State/Province
Lombardia
ZIP/Postal Code
27100
Country
Italy
City
Aguascaliente
ZIP/Postal Code
20230
Country
Mexico
City
Chihuahua
ZIP/Postal Code
31238
Country
Mexico
City
Cuernavaca
ZIP/Postal Code
62250
Country
Mexico
City
Durango
ZIP/Postal Code
34080
Country
Mexico
City
Guadalajara
ZIP/Postal Code
44600
Country
Mexico
City
Guadalajara
ZIP/Postal Code
44650
Country
Mexico
City
Pachuca
ZIP/Postal Code
42060
Country
Mexico
City
Pachuca
ZIP/Postal Code
42090
Country
Mexico
City
Arequipa
ZIP/Postal Code
Cercado
Country
Peru
City
Lima
ZIP/Postal Code
11
Country
Peru
City
Lima
ZIP/Postal Code
LIMA 29
Country
Peru
City
Bucharest
ZIP/Postal Code
020475
Country
Romania
City
Cluj-napoca
ZIP/Postal Code
400006
Country
Romania
City
Iasi
ZIP/Postal Code
700 503
Country
Romania
City
Ploiesti
ZIP/Postal Code
100163
Country
Romania
City
Sibiu
ZIP/Postal Code
550245
Country
Romania
City
Targu Mures
ZIP/Postal Code
540142
Country
Romania
City
Chelyabinsk
ZIP/Postal Code
454047
Country
Russian Federation
City
Moscow
ZIP/Postal Code
119121
Country
Russian Federation
City
Moscow
ZIP/Postal Code
121069
Country
Russian Federation
City
Moscow
ZIP/Postal Code
125101
Country
Russian Federation
City
Moscow
ZIP/Postal Code
127299
Country
Russian Federation
City
Moscow
ZIP/Postal Code
129110
Country
Russian Federation
City
Saint-Petersburg
ZIP/Postal Code
194156
Country
Russian Federation
City
Saratov
ZIP/Postal Code
140018
Country
Russian Federation
City
St Petersburg
ZIP/Postal Code
195067
Country
Russian Federation
City
St Petersburg
ZIP/Postal Code
195257
Country
Russian Federation
City
St Petersburg
ZIP/Postal Code
197089
Country
Russian Federation
City
Yaroslavl
ZIP/Postal Code
150062
Country
Russian Federation
City
Bratislava
ZIP/Postal Code
821 02
Country
Slovakia
City
Dolny Kubin
ZIP/Postal Code
026 01
Country
Slovakia
City
Levice
ZIP/Postal Code
034 01
Country
Slovakia
City
Lucenec
ZIP/Postal Code
984 01
Country
Slovakia
12. IPD Sharing Statement
Citations:
PubMed Identifier
25407798
Citation
Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M. Effects of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180.
Results Reference
derived
Learn more about this trial
A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
We'll reach out to this number within 24 hrs